Department of Medicine and Division of Gastroenterology and Hepatology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Department of Diagnostics and New Technologies, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Gastrointest Endosc. 2018 Jul;88(1):175-184.e1. doi: 10.1016/j.gie.2018.02.022. Epub 2018 Feb 22.
The early improvement in metabolic profile after sleeve gastrectomy (SG) indicates that the significant benefits of metabolic surgery are gastric in origin. We have previously demonstrated that devitalization of the gastric mucosa (without a reduction in gastric volume) in metabolically disturbed obese rats results in an improvement of obesity and its associated comorbidities. The aims of this study were to assess the technical feasibility, efficacy, and safety of gastric mucosal devitalization (GMD) in a large animal (porcine) model.
A 3-arm (GMD versus SG versus sham [SH]) prospective randomized controlled trial with an 8-week follow-up period was performed. The primary endpoint was relative weight loss. Secondary endpoints were absolute body weight, abdominal visceral adiposity, abdominal subcutaneous adiposity, organ lipid content, and serum ghrelin level.
GMD resulted in a significant relative weight loss of 36% over SH at 8 weeks (P < .05). There was no significant difference in relative weight loss between GMD and SG at 4 weeks; however, SG resulted in a 29% superior relative weight loss at 8 weeks (P < .05). With regard to visceral adiposity, there was a significant benefit of GMD over SH at 8 weeks. Despite differences in relative weight loss, there was no significant difference in visceral adiposity between SG and GMD at 8 weeks. Significant improvements in GMD over SH were noted with regard to skeletal and heart muscle lipid content. GMD pigs at 8 weeks demonstrated regeneration of the gastric mucosa without ulceration or significant scarring. Despite mucosal regeneration, the abundance of serum ghrelin was significantly lower in the GMD cohort compared with the SG and SH cohorts.
GMD was technically feasible and resulted in relative weight loss and an improvement in visceral adiposity. The benefits noted were out of proportion to what would be expected with weight loss alone.
袖状胃切除术(SG)后代谢谱的早期改善表明代谢手术的显著益处源于胃。我们之前已经证明,代谢紊乱肥胖大鼠胃黏膜失活(不减少胃容量)可导致肥胖及其相关合并症的改善。本研究的目的是评估胃黏膜失活(GMD)在大型动物(猪)模型中的技术可行性、疗效和安全性。
进行了一项为期 8 周的前瞻性随机对照三臂(GMD 与 SG 与假手术 [SH])试验。主要终点是相对体重减轻。次要终点是绝对体重、腹部内脏脂肪、腹部皮下脂肪、器官脂质含量和血清 ghrelin 水平。
GMD 在 8 周时导致相对体重减轻 36%,与 SH 相比差异有统计学意义(P<0.05)。GMD 与 SG 在 4 周时的相对体重减轻无显著差异;然而,SG 在 8 周时导致相对体重减轻 29%,差异有统计学意义(P<0.05)。就内脏脂肪而言,GMD 与 SH 相比在 8 周时有显著获益。尽管相对体重减轻存在差异,但 SG 与 GMD 在 8 周时内脏脂肪无显著差异。GMD 与 SH 相比,骨骼肌和心肌脂质含量有显著改善。8 周时 GMD 猪胃黏膜再生,无溃疡或明显瘢痕。尽管胃黏膜再生,但 GMD 组血清 ghrelin 的丰度明显低于 SG 组和 SH 组。
GMD 技术上可行,可导致相对体重减轻和内脏脂肪改善。所观察到的益处与仅体重减轻所预期的不成比例。